ASAHI-KASEI
13.1.2021 17:02:37 CET | Business Wire | Press release
Asahi Kasei's Specialty Solutions SBU will build a second plant for microcrystalline cellulose [1] (trade name Ceolus™) at its Mizushima Works in Kurashiki, Okayama, Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210113005028/en/
Asahi Kasei currently manufactures Ceolus™, a microcrystalline cellulose used primarily in pharmaceuticals as tablet binder [2], in Nobeoka, Miyazaki, Japan.
Besides the standard-type product PH series, Ceolus™ has a lineup of KG series that greatly enhances the compactibility of tablets, and UF series that combines compactibility and flowability. These products provide solutions to a wide range of issues in the production of tablets for pharmaceuticals and supplements.
By using the KG series, tablets can be produced stably even when the amount of tablet binder that can be added is small, such as when tablets contain a large amount of active pharmaceutical ingredient (API) or when multiple APIs are formulated in a single tablet.
The UF series realizes stable production of tablets as well as the uniformity of contained API in tablets, which depend on the excellent flowability of the product.
In recent years, demand for proprietary KG and UF series products has increased, and further growth in demand is expected in the future. To meet such growing demand, Asahi Kasei has decided to make a capital expenditure to double the production capacity and achieve a stable supply through multiple production sites. This expansion will enable Asahi Kasei to meet the needs of the pharmaceutical and supplement industries and to contribute to life and living for people around the world.
[1] Microcrystalline cellulose is a white powder made from natural pulp, mainly used as an excipient for pharmaceuticals and foods
[2] Tablet binders are additives used for the purpose of providing the shape and increasing the volume of solid tablets
Capital Expenditure |
||
Location: |
Asahi Kasei Corporation Mizushima Works |
|
|
Kurashiki City, Okayama Prefecture, Japan |
|
Construction schedule: |
Groundbreaking in September 2021 |
|
|
Completion in Spring 2023 |
|
Investment amount: |
¥13 billion ($126 million at ¥103/$) |
|
Product: |
Ceolus™ microcrystalline cellulose |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005028/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SuperElastic* Material Unveiled by Angelalign2.11.2026 18:46:00 CET | Press release
New, Improved Clear Aligner Material Gives Orthodontists More Control Angelalign Technology Inc. (6699.HK) (“Angel”)http://www.angelaligner.com, a global clear aligner leader, today unveiled SuperElastic (MC-SE*), a new propietary aligner material that is a significant breakthrough in performance over its current material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102654659/en/ Specialists in orthodontics have long asked for new aligner materials that enable better treatment for complex cases: biologically safe force levels, a large elastic working range, and strength and toughness. MC-SE* provides all of them. “Angel is commited to innovation and never settling for 'good enough'. MC-SE* is the result of seven years of materials research, testing and manufacturing optimization. The new material aims to create a new generation of aligner material that allows orthodonists to differentiate their treatment from other tre
Galderma Announces Proposed Board Appointments and Chief Financial Officer Transition2.11.2026 18:00:00 CET | Press release
The Company will hold an Extraordinary General Meeting on December 3, 2026 to further reinforce its Board of DirectorsAd hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced proposed changes to its Board of Directors, aimed at further strengthening its governance and supporting its long-term growth. The company also announced that Luigi La Corte, Chief Financial Officer (CFO), has decided to leave Galderma to pursue a significant new opportunity. Luigi La Corte will continue to fulfil his responsibilities as CFO during the transition period, supporting business continuity and a smooth handover. The company will communicate further details regarding succession arrangements and the transition timeline in due course. The Board of Directors is proposing the election of Rosalind Brewer and Petra Rumpf as new Board members. Both candidates bring extensive leadership and governance experience, alongside expertise span
Donaldson Introduces Alpha-Pore™ Technology Platform for Extended Sterile Filtration Performance2.11.2026 15:35:00 CET | Press release
Donaldson Company, Inc. (NYSE: DCI), a leading worldwide manufacturer of innovative filtration products and solutions, today announced Alpha‑Pore™ technology, a next generation sterile filtration platform engineered to extend filter service life while maintaining critical process performance. Built for critical applications, Alpha‑Pore technology enables longer filter run time compared with competitive single- and dual-layer polyethersulfone (PES) membrane filters, while maintaining flow characteristics, sterility assurance, and process integrity.* The platform is designed to help manufacturers improve operational efficiency through fewer changeouts and more consistent performance over time. Engineered for Extended Performance Sterile filtration processes often require balancing run time with key performance parameters such as flow, differential pressure, and contaminant retention. Alpha‑Pore technology is designed to achieve all three. By optimizing pore structure and filter architect
SBC Medical Forms Capital and Business Alliance with AtomicSoftware, Provider of the medicalforce Clinic Management Platform Used by 800+ Clinics in Japan2.11.2026 15:00:00 CET | Press release
Companies to co-develop AI features, starting with physician documentation support, to enhance medicalforce and SBC Medical’s in-house systems and drive per-clinic productivity and profitability SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it entered into a capital and business alliance agreement on October 26, 2026, with AtomicSoftware Inc. (“AtomicSoftware”), the Tokyo-based provider of medicalforce, an all-in-one software-as-a-service (SaaS) platform for clinics. In connection with the alliance, SBC Medical has invested ¥600 million (approximately US$3.8 million) in AtomicSoftware’s Series C funding round. The two companies will co-develop AI features, beginning with a feature that supports physicians in preparing medical records. Key HighlightsProven platform: medicalforce is used by more than 800 clinics*1 in J
Smartly Launches Intelligence Pro to Connect Campaign Planning, Performance and Incrementality2.11.2026 15:00:00 CET | Press release
The new offering brings together planning, performance benchmarks, headroom analysis and incrementality signals to help marketers make more informed decisions across the campaign lifecycle Smartly, the AI-powered advertising technology company, today launched Intelligence Pro, a premium offering that brings together four capabilities to help marketers plan investment, understand true incrementality and determine where to spend their next dollar. Intelligence Pro connects causal inference models with planning tools to help marketers prove business impact and make faster decisions from increasingly complex data. “Marketing teams are inundated with data, but the challenge is identifying what signals are useful and turning them into a decision they can act on,” said Maxwell Tang, Chief Product Officer at Smartly. “Intelligence Pro brings forecasting, market context and state-of-the-art incrementality signals together to help marketers assess where to invest and what their media is contribu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom